Neumora Therapeutics

Market position

Neumora positions itself as a precision-medicine challenger in neuroscience, where treatment for prevalent conditions such as major depressive disorder has been dominated by a narrow set of drug classes (e.g., serotonin-targeting antidepressants) and where clinical failure rates are high. The company states brain diseases affect upwards of 1.5 billion people. Its market capitalization of roughly $300 million places it among smaller listed biotech companies; publicly listed peers cited include Alto Neuroscience, Minerva Neurosciences and Rapport Therapeutics. Management has acknowledged competition from biotech and large pharmaceutical companies pursuing similar mechanisms, including NLRP3 inhibitors.

Stated differentiators are the integration of data science with neuroscience to segment heterogeneous brain diseases into biologically defined patient subtypes (Data Biopsy Signatures and Precision Phenotypes), a pipeline of programs each pursuing a novel mechanism of action with intended best-in-class pharmacology, and enrichment of trial populations to raise probability of success versus one-size-fits-all development. Its chief scientific officer framed the key differentiator as taking molecules into more targeted subpopulations predicted to respond better.

Technology

Neumora's approach centers on a scalable precision data science platform, described as a Precision Toolbox integrating translational, clinical and computational tools. Proprietary neural-network technologies integrate genomics, imaging, EEG, digital and clinical data drawn from open-source and proprietary datasets to create Data Biopsy Signatures, which map underlying disease mechanisms to Precision Phenotypes identifying distinct patient subtypes. The intent is to match patient populations to targeted therapeutics, de-risking clinical trials. Behavioral analysis technology using computer vision and machine learning to detect subtle patterns in animal behavior came from the acquisition of Syllable Life Sciences. Therapeutic modalities are primarily small molecules directed at novel mechanisms of action.

Go-to-market

As a clinical-stage developer, Neumora advances candidates through clinical trials toward regulatory approval; it has used partnerships and licensing (Amgen collaboration and equity investment, Vanderbilt University license) and acquisitions of private companies to build its portfolio, and has raised capital from venture, sovereign and strategic investors and subsequently public equity markets.

Patients with central nervous system disorders, including major depressive disorder, agitation associated with Alzheimer's dementia, schizophrenia and other neuropsychiatric conditions, Parkinson's disease, ALS, anxiety disorders, sleep disorders and obesity. MDD alone is estimated to affect over 21 million U.S. adults, with nearly 70% of patients failing to achieve remission on first-line treatment.

Geography

Headquartered in Watertown, Massachusetts, with a team also based in San Francisco at the time of launch; development activity is described as focused in the United States. One source lists the headquarters as Cambridge, Massachusetts.

History

Incorporated in 2019 as RBNC Therapeutics, Inc. and operated in stealth by ARCH Venture Partners, the company launched publicly on October 7, 2021 with over $500 million raised, comprising a $400 million Series A led by ARCH and a $100 million equity investment from Amgen, alongside a strategic research collaboration with Amgen. It renamed itself Neumora Therapeutics in October 2021. By launch it had acquired four smaller startups — including Blackthorn Therapeutics (source of its kappa opioid and V1a receptor antagonists), Alairion (sleep-disorder candidate), Syllable Life Sciences (machine-vision behavioral analysis) and Abelian Therapeutics (glial cell biology) — and licensed CK1delta and glucocerebrosidase programs from Amgen. In February 2022 it signed an exclusive worldwide license and research collaboration with Vanderbilt University's Warren Center for Neuroscience Drug Discovery for M4 muscarinic PAMs. In October 2022 it closed a $112 million Series B, bringing total capital raised to roughly $650 million. The company subsequently listed on Nasdaq under the ticker NMRA. In 2026, navacaprant was discontinued after pivotal MDD trial failures, prompting staffing cuts, while the company reported favorable NMRA-215 toxicology results with planned clinical advancement in 2026.

Risks & controversies

Three pivotal major depressive disorder trial failures led to the discontinuation of navacaprant, a roughly 49% single-day share decline and staffing cuts; the stock is down approximately 90% over five years and traded near $1.60-$1.73 versus a 52-week range of $0.83-$3.65. The company generates no revenue, reported a trailing-twelve-month net loss of $222.4 million and negative levered free cash flow of $108.3 million against $147.1 million of cash, implying financing risk. Multiple analysts cut price targets in mid-2026 and Wall Street Zen rated the stock "sell." Sources also conflict on headquarters location (Watertown vs. Cambridge) and on the size and count of funding rounds.